TrialInvestigational new drugs2018

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.

Herbert Hurwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.